- Home
- MYGN vs BHK Comparison
MYGN vs BHK Comparison
Compare MYGN & BHK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- BHK
- Stock Information
- Founded
- MYGN 1991
- BHK 2001
- Country
- MYGN United States
- BHK United States
- Employees
- MYGN N/A
- BHK N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- BHK Finance Companies
- Sector
- MYGN Health Care
- BHK Finance
- Exchange
- MYGN Nasdaq
- BHK Nasdaq
- Market Cap
- MYGN 642.0M
- BHK 725.1M
- IPO Year
- MYGN 1995
- BHK N/A
- Fundamental
- Price
- MYGN $7.96
- BHK $10.08
- Analyst Decision
- MYGN Hold
- BHK
- Analyst Count
- MYGN 13
- BHK 0
- Target Price
- MYGN $13.50
- BHK N/A
- AVG Volume (30 Days)
- MYGN 1.5M
- BHK 188.3K
- Earning Date
- MYGN 11-06-2025
- BHK 01-01-0001
- Dividend Yield
- MYGN N/A
- BHK 8.34%
- EPS Growth
- MYGN N/A
- BHK N/A
- EPS
- MYGN N/A
- BHK 1.03
- Revenue
- MYGN $832,900,000.00
- BHK N/A
- Revenue This Year
- MYGN $0.17
- BHK N/A
- Revenue Next Year
- MYGN $6.19
- BHK N/A
- P/E Ratio
- MYGN N/A
- BHK $10.42
- Revenue Growth
- MYGN 3.83
- BHK N/A
- 52 Week Low
- MYGN $3.76
- BHK $9.02
- 52 Week High
- MYGN $26.60
- BHK $11.09
- Technical
- Relative Strength Index (RSI)
- MYGN 57.10
- BHK 73.45
- Support Level
- MYGN $7.04
- BHK $9.96
- Resistance Level
- MYGN $8.25
- BHK $10.04
- Average True Range (ATR)
- MYGN 0.38
- BHK 0.06
- MACD
- MYGN -0.06
- BHK 0.02
- Stochastic Oscillator
- MYGN 54.77
- BHK 97.97
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About BHK Blackrock Core Bond Trust
Blackrock Core Bond Trust is a closed-ended management investment company. Its objective is to provide current income and capital appreciation. The trust seeks to achieve its investment objective by investing a majority of its managed assets in bonds that are investment-grade quality at the time of investment. The trust's investments will include a broad range of bonds, including corporate bonds, U.S. government and agency securities and mortgage-related securities.